---
figid: PMC7037946__ijms-21-00753-g001
figtitle: Physiological and rearranged NTRK genes/TRK receptors and intracellular
  signaling
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC7037946
filename: ijms-21-00753-g001.jpg
figlink: pmc/articles/PMC7037946/figure/ijms-21-00753-f001/
number: F1
caption: Physiological and rearranged NTRK genes/TRK receptors and intracellular signaling.
  The PLC-γ, MAPK, and PI3-K intracellular pathways (here represented by the DAG/IP3,
  RAS/MEK/ERK, and PI3-K/AKT components, respectively) are activated either from the
  wild-type form of NTRK, and the chimeric fusion receptors (e.g., BCAN-NTRK1 and
  ETV6-NTRK3). However, the latter happens in a ligand-free constitutively activated
  fashion, leading to oncogenic activation. The NTRK inhibitors (TKI, here represented
  by entrectinib and larotrectinib) achieve their antitumor activity by interacting
  with the intracellular domain of the chimeric receptors, inhibiting the recruitment
  of the signaling pathway.
papertitle: 'NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.'
reftext: Alessandro Gambella, et al. Int J Mol Sci. 2020 Feb;21(3):753.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9208006
figid_alias: PMC7037946__F1
figtype: Figure
redirect_from: /figures/PMC7037946__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7037946__ijms-21-00753-g001.html
  '@type': Dataset
  description: Physiological and rearranged NTRK genes/TRK receptors and intracellular
    signaling. The PLC-γ, MAPK, and PI3-K intracellular pathways (here represented
    by the DAG/IP3, RAS/MEK/ERK, and PI3-K/AKT components, respectively) are activated
    either from the wild-type form of NTRK, and the chimeric fusion receptors (e.g.,
    BCAN-NTRK1 and ETV6-NTRK3). However, the latter happens in a ligand-free constitutively
    activated fashion, leading to oncogenic activation. The NTRK inhibitors (TKI,
    here represented by entrectinib and larotrectinib) achieve their antitumor activity
    by interacting with the intracellular domain of the chimeric receptors, inhibiting
    the recruitment of the signaling pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Shc
  - dos
  - Erk7
  - rl
  - Dsor1
  - Mtk
  - ras
  - Ras64B
  - Ras85D
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - NTRK1
  - NTRK2
  - NTRK3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - GAB1
  - PIGU
  - EPHB2
  - MAPK1
  - MAPK3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BCAN
---
